Leo Pharma

NCT00833872

LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects

NCT00891709

LEO 29102 Single and Multiple Dose Study by Dermal Application

NCT00958516

Assessment of the Phototoxic Potential of LEO 29102 Cream

NCT01007383

LEO 27847 - A Study in Healthy Male Subjects

NCT01005823

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

NCT01043224

A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris

NCT01105234

An Irritation Study With New Calcipotriol Ointment Formulations in Healthy Subjects

NCT01105286

A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis

NCT01141179

The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

NCT01143298

LEO 27847 - Single Dose Bioavailability Study of Oral Solution Versus Tablet in Healthy Subjects

NCT01167309

LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients

NCT01211964

LEO 22811 - Single Dose Bioavailability Study of Tablet Versus Oral Solution in Healthy Subjects

NCT01293357

A Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects

NCT01257919

Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea

NCT01297166

A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris

NCT01302925

PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects

NCT01293383

A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects

NCT01310049

LEO 32731 - A Study in Healthy Male Subjects

NCT01387711

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

NCT01423656

Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102

NCT01430312

21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation

NCT01430533

Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation

NCT01447758

Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.

NCT01449513

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

NCT01466478

An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris

NCT01580488

A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris

NCT01703078

Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis

NCT01836367

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

NCT01947738

Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)

NCT01837576

An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris

NCT01850849

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

NCT01892137

Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%

NCT01935869

Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100

NCT01946386

A Vasoconstriction Study With LEO 90100

NCT02103725

A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis

NCT02124239

Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions

NCT02126371

LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects

NCT02219633

Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

NCT02355639

A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin

NCT02376049

A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)

NCT02379793

Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects

NCT02392130

A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin

NCT02411851

Treatment of Actinic Keratoses (AK) on the Face

NCT02424305

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

NCT02496546

An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

NCT02514694

LEO 32731 - A Phase I Study in Healthy Subjects

NCT02577185

An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A

NCT02605057

Dermatopharmacokinetic Trial of LEO 80185 Gel

NCT02650505

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

NCT02748902

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

NCT02753218

A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects

NCT02600598

Biological Effects of LEO 43204 in Actinic Keratosis

NCT02973776

Vasoconstriction Trial With LEO 90100 Aerosol Foam

NCT03126578

Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam

NCT03231124

Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

NCT03442244

Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

NCT03476746

Dermatopharmacokinetic Trial of LEO 90100 Foam

NCT03514511

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

NCT03556592

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

NCT03669757

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

NCT03673527

Tacrolimus Blood Levels After Topical Application of Tacrolimus on Healthy Skin

NCT03812198

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

NCT03826901

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

NCT03898583

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.

NCT03995550

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese

NCT04203836

A Trial to Evaluate the Effect of Food on LEO 152020

NCT04361136

Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream

NCT04674826

A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects

NCT04807751

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

NCT04883333

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults

NCT05099133

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

NCT05486117

Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema

NCT05508776

A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People

NCT05682352

Investigating the Safety of LEO 158968 in Healthy Volunteers

NCT06444867

A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968